Allurion Technologies, INC 8-K filings

Allurion Technologies' Chief Financial Officer, Christopher Geberth, has resigned, effective November 13, 2024, with CEO Shantanu Gaur temporarily taking over financial responsibilities.

Allurion Technologies reported a significant revenue decrease in Q3 2024, alongside a restructuring plan aimed at reducing operating expenses and achieving profitability by the end of 2025.

Allurion Technologies has entered into a new revenue interest financing agreement, converting $7.5 million of a previous investment into additional financing.

Allurion Technologies has announced the date for its first annual meeting of stockholders, scheduled for December 11, 2024.

Allurion Technologies has received a notice from the NYSE for not meeting the minimum market capitalization standard, placing its listing at risk.

Allurion Technologies has appointed Keith Johns, a former Eli Lilly executive with extensive experience in the obesity market, to its Board of Directors.

Allurion Technologies has received a notice from the NYSE for non-compliance with listing standards due to its stock price falling below $1.00, triggering a potential delisting.

Allurion Technologies announced a 25% sequential revenue increase in Q2 2024, alongside record procedure volume and a business update.

Allurion Technologies has suspended sales of its Allurion Balloon in France after the French regulatory authority, ANSM, raised concerns about advertising, follow-up programs, and adverse events.

Allurion Technologies partially exercised an over-allotment option, generating approximately $2.3 million in additional gross proceeds.

Allurion Technologies has announced the pricing of a $20 million public offering and concurrent private placement to fund clinical trials, commercial sales, and research and development.

Allurion Technologies is raising $20 million to fund clinical trials, commercial sales, research and development, and for working capital, while also providing an update on its business and growth strategy.

Allurion Technologies announced its first quarter 2024 financial results, showing a 14% sequential increase in revenue and a significant reduction in cash burn.

Allurion reported preliminary first quarter 2024 results showing revenue growth, increased procedural volume, and a significant reduction in cash burn.

Allurion Technologies closes a $48 million convertible senior secured note financing with RTW Investments, simplifying its capital structure and extending its cash runway.

Allurion Technologies reported a decrease in fourth-quarter revenue but saw a 30% increase in procedural volume for 2023, while reiterating its 2024 financial guidance.

Allurion Technologies has appointed Milena Alberti-Perez to its Board of Directors as a Class III director and Audit Committee Chair, effective March 11, 2024.